XENON PHARMACEUTICALS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.78 USD | -1.39% |
|
-2.59% | -14.26% |
Presenter SpeechKyuwon Choi (Analysts)Okay. Good morning. We'll continue with our next session...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Calendar
2024-06-04
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
40.34
USD
Average target price
57.26
USD
Spread / Average Target
+41.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.26% | 3.04B | |
| +9.59% | 114B | |
| +11.54% | 104B | |
| -13.98% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.36% | 17.89B | |
| +7.17% | 14.28B | |
| +35.90% | 12.55B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Transcript : Xenon Pharmaceuticals Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 10